Astellas 製藥 ：製藥企業分析報告 是由出版商Espicom Business Intelligence在2010年01月所出版的。
這份英文市場調查報告書包含Pages: 146 價格從美金1040起跳。
Abstract
On 1st April 2005, Yamanouchi Pharmaceutical Co Ltd. and Fujisawa
Pharmaceutical Co., Ltd. merged. Yamanouchi, the surviving company, was renamed
Astellas, and Fujisawa was dissolved (merger ratio = Yamanouchi: Fujisawa
1:0.71). Headquarters for the combined business are in Tokyo, Japan, with
locally operated Regional Headquarters in the US, Europe and Asia.
The aim of Astellas is to secure a top share in the Japanese pharmaceutical
market; the combined company now has 5,000 medical representatives, the
largest among domestic pharmaceutical companies, and it aims to develop an
even stronger sales and marketing infrastructure. The company also expects to
be able to provide broad coverage for both primary care physicians and
speciality markets in the US by leveraging the existing infrastructures to
accelerate expansion of the US business.
The combined company is aiming to achieve economies of scale through the
integration of the R&D, and sales and marketing capabilities of both the
companies, as well as to further improve its profitability through the
establishment of more efficient operational structures.
Astellas has a broad portfolio, with strength in the areas of Cardiovascular,
Inflammation/Immunology, Urology, Gastrointestinal, Central Nervous System and
Infectious Disease.
This new strategic analysis report Astellas Pharma: Pipeline - Products -
Performance - Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- CARDIOVASCULAR
- Marketed Products
- Adenoscan
- Lipitor
- Lexiscan
- Micardis
- Others
- R&D Projects
- ASP1585
- Kynapid
- YM150
- YM311
- Growth Forecast
- INFLAMM ATION & IMM UNOLOGY
- Marketed Products
- R&D Projects
- AGI-1096
- ASKP1240
- ASP015K
- Symbicort
- Growth Forecast
- UROLOGY
- Marketed Products
- Harnal/Omnic/Flomax
- Vesicare
- R&D Projects
- Growth Forecast
- INFECTIOUS DISE ASE
- Marketed Products
- Funguard/Mycamine
- Geninax
- Vibativ
- Others
- R&D Projects
- Growth Forecast
- GASTR OINTEST INAL
- Marketed Products
- R&D Projects
- Growth Forecast
- CENTR AL NER VOUS SYSTEM
- Marketed Products
- R&D Projects
- ASP2905
- ASP8825
- CTS-21166
- Growth Forecast
- DERM ATOLOGY
- Marketed Products
- Growth Forecast
- ONCOLOGY
- Marketed Products
- R&D Projects
- AC220
- AGS-1C4D4
- AGS-16M18
- AGS-8M4
- ASP0265
- MDV3100
- Degarelix
- YM155
- Growth Forecast
- Other Areas
- Marketed Products
- R&D Projects
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Ajinomoto Co Inc.
- American BioScience Inc. (ABS)
- AstraZeneca
- AtheroGenics Inc.
- Biogen Idec
- Boehringer Ingelheim (BI)
- Cardiome Pharma Corp.
- Cephalon Inc.
- CoMentis Inc.
- CV Therapeutics Inc. (CVT)
- Ferring Pharmaceuticals
- FibroGen Inc.
- Gilead Sciences Inc.
- GlaxoSmithKline
- Gloucester Pharmaceuticals Inc
- Ilypsa Inc.
- Immuno-Biological Laboratories
- Ironwood Pharmaceuticals
- Kirin Brewery
- Maxygen Inc.
- Medivation Inc.
- Metabolex Inc.
- MorphoSys AG
- Mundipharma International
- Neurosearch A/S
- NeurogesX Inc
- Nippon Kayaku Co Ltd.
- Novartis
- Ono Pharmaceutical Co Ltd.
- Pfizer
- Regeneron Pharmaceuticals Inc.
- Seattle Genetics
- sanofi-aventis
- Senju Pharmaceutical Co., Ltd.
- SymBio Pharmaceuticals Ltd.
- Taiho Pharmaceuticals Co., Ltd.
- Taisho Toyama Pharmaceutical Co., Ltd.
- Tercica Inc.
- Theravance Inc.
- Wyeth
- XenoPort Inc.
- Zeria Pharmaceutical Co Ltd.
- Zogenix
- APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Sales By Business Area
- Sales By Destination
- Sales By Origin
- Operating Income (Loss) By Geographic Area
- Total Assets By Geographical Area
- Employees By Geographic Area
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Cardiovascular Products, 2009
- Major Inflammation & Immunology Products, 2009
- Major Urology Products, 2009
- Major Infectious Disease Products, 2009
- Major Gastrointestinal Products, 2009
- Major Central Nervous System Products, 2009
- Major Dermatology Products, 2009
- Major Oncology Products, 2009
- Major Other Products, 2009
INDEX OF CHARTS
- Sales By Business Area
- Sales By Destination
- Sales By Origin
- Operating Income (Loss) By Geographic Area
- Total Assets By Geographical Area
- Employees By Geographic Area, 2009
- Sales of Current Top Ten Products (2004A-2014E)
- Adenoscan Sales (2004A-2014E)
- Lipitor Sales (2004A-2014E)
- Lexiscan Sales (2009E-2015E)
- Micardis Sales (2004A-2014E)
- Kynapid Sales (2010E-2014E)
- Celecox Sales (2004A-2014E)
- Prograf Sales (2004A-2014E)
- Flomax/Harnal/Omnic Sales (2004A-2014E)
- Vesicare Sales (2004A-2014E)
- Funguard Sales (2004A-2014E)
- Geninax Sales (2008E-2014E)
- Vibativ Sales (2010E-2014E)
- Gaster/Pepcid Sales (2004A-2014E)
- Myslee Sales (2004A-2014E)
- Seroquel Sales (2004A-2014E)
- Protopic Sales (2004A-2014E)
- Eligard Sales (2006A-2014E)
- Minodronate Sales (2010E-2014E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
